Loading...
XNASANL
Market cap69mUSD
Dec 23, Last price  
2.22USD
1D
2.77%
1Q
7.24%
IPO
-83.05%
Name

Adlai Nortye Ltd

Chart & Performance

D1W1MN
XNAS:ANL chart
P/E
P/S
13.88
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
5m
0045,726,00004,995,653
Net income
-105m
L+78.38%
-17,830,042-63,378,317-56,678,000-58,790,000-104,871,000
CFO
-57m
L+31.07%
-14,923,758-34,594,594-3,034,000-43,223,000-56,652,000

Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.
IPO date
Sep 29, 2023
Employees
Domiciled in
KY
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
4,996
 
45,726
 
Cost of revenue
75,661
69,568
54,555
Unusual Expense (Income)
NOPBT
(70,665)
(69,568)
(8,829)
NOPBT Margin
Operating Taxes
643
8,312
(46,188)
Tax Rate
NOPAT
(71,308)
(77,880)
37,359
Net income
(104,871)
78.38%
(58,790)
3.73%
(56,678)
-10.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
91,780
BB yield
-70.66%
Debt
Debt current
31,079
5,308
11,291
Long-term debt
1,660
3,473
4,942
Deferred revenue
Other long-term liabilities
297,563
Net debt
(90,609)
(55,264)
(101,707)
Cash flow
Cash from operating activities
(56,652)
(43,223)
(3,034)
CAPEX
(200)
(1,268)
(1,120)
Cash from investing activities
(10,954)
28,376
(54,857)
Cash from financing activities
116,240
(6,780)
97,200
FCF
(310,273)
164,273
(13,357)
Balance
Cash
98,499
64,045
117,940
Long term investments
24,849
Excess cash
123,098
64,045
115,654
Stockholders' equity
(377,322)
(261,396)
(199,449)
Invested Capital
488,273
26,647
324,929
ROIC
18.52%
ROCE
29.63%
EV
Common stock shares outstanding
14,447
8,480
8,480
Price
8.99
 
Market cap
129,882
 
EV
39,273
EBITDA
(68,445)
(67,527)
(7,001)
EV/EBITDA
Interest
791
433
579
Interest/NOPBT